-
World Health Organization. 2012a. Outbreak news. Ebola, Democratic Republic of the Congo. Wkly Epidemiol Rec, 87: 421.
-
World Health Organization. 2012b. Outbreak news. Marburg haemorrhagic fever, Uganda. Wkly Epidemiol Rec, 87: 414.
-
Basler C F, and Amarasinghe G K. 2009. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res, 29: 511-520.
doi: 10.1089/jir.2009.0076
-
Bavari S, Bosio C M, Wiegand E, Ruthel G, Will A B, Geisbert T W, Hevey M, Schmaljohn C, Schmaljohn A, and Aman M J. 2002. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med, 195: 593-602.
doi: 10.1084/jem.20011500
-
Bosio C M, Moore B D, Warfield K L, Ruthel G, Mohamadzadeh M, Aman M J, and Bavari S. 2004. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology, 326: 280-287.
doi: 10.1016/j.virol.2004.05.025
-
Bosio C M, Aman M J, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, and Schmaljohn A. 2003. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis, 188: 1630-1638.
doi: 10.1086/jid.2003.188.issue-11
-
Bradfute S B, Dye J M, Jr., and Bavari S. 2011. Filovirus vaccines. Hum Vaccin, 7: 701-711.
doi: 10.4161/hv.7.6.15398
-
Bray M, Davis K, Geisbert T, Schmaljohn C, and Huggins J. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis, 178: 651-661.
doi: 10.1086/jid.1998.178.issue-3
-
Cardenas W B, Loo Y M, Gale M, Jr., Hartman A L, Kimberlin C R, Martinez-Sobrido L, Saphire E O, and Basler C F. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol, 80: 5168-5178.
doi: 10.1128/JVI.02199-05
-
Chang T H, Kubota T, Matsuoka M, Jones S, Bradfute S B, Bray M, and Ozato K. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog, 5: e1000493.
doi: 10.1371/journal.ppat.1000493
-
Feldmann H, Klenk H D, and Sanchez A. 1993. Molecular biology and evolution of filoviruses. Arch Virol Suppl, 7: 81-100.
doi: 10.1007/978-3-7091-9300-6
-
Johnson R F, Bell P, and Harty R N. 2006. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J, 3: 31.
doi: 10.1186/1743-422X-3-31
-
Leung L W, Park M S, Martinez O, Valmas C, Lopez C B, and Basler C F. 2011. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol, 89: 792-802.
doi: 10.1038/icb.2010.169
-
Licata J M, Johnson R F, Han Z, and Harty R N. 2004. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol, 78: 7344-7351.
doi: 10.1128/JVI.78.14.7344-7351.2004
-
Makino A, Yamayoshi S, Shinya K, Noda T, and Kawaoka Y. 2011. Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding. J Infect Dis, 204 Suppl 3: S871-877.
-
Martinez O, Valmas C, and Basler C F. 2007. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology, 364: 342-354.
doi: 10.1016/j.virol.2007.03.020
-
Okumura A, Pitha P M, and Harty R N. 2008. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A, 105: 3974-3979.
doi: 10.1073/pnas.0710629105
-
Sullivan N J, Martin J E, Graham B S, and Nabel G J. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol, 7: 393-400.
doi: 10.1038/nrmicro2129
-
Swenson D L, Warfield K L, Negley D L, Schmaljohn A, Aman M J, and Bavari S. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine, 23: 3033-3042.
doi: 10.1016/j.vaccine.2004.11.070
-
Swenson D L, Warfield K L, Kuehl K, Larsen T, Hevey M C, Schmaljohn A, Bavari S, and Aman M J. 2004. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol, 40: 27-31.
doi: 10.1016/S0928-8244(03)00273-6
-
Swenson D L, Wang D, Luo M, Warfield K L, Woraratanadharm J, Holman D H, Dong J Y, and Pratt W D. 2008. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol, 15: 460-467.
doi: 10.1128/CVI.00431-07
-
Wahl-Jensen V, Kurz S K, Hazelton P R, Schnittler H J, Stroher U, Burton D R, and Feldmann H. 2005. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol, 79: 2413-2419.
doi: 10.1128/JVI.79.4.2413-2419.2005
-
Wahl-Jensen V, Kurz S, Feldmann F, Buehler L K, Kindrachuk J, DeFilippis V, da Silva Correia J, Fruh K, Kuhn J H, Burton D R, and Feldmann H. 2011. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis, 5: e1359.
doi: 10.1371/journal.pntd.0001359
-
Wahl-Jensen V M, Afanasieva T A, Seebach J, Stroher U, Feldmann H, and Schnittler H J. 2005. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol, 79: 10442-10450.
doi: 10.1128/JVI.79.16.10442-10450.2005
-
Warfield K L, Deal E M, and Bavari S. 2009. Filovirus infections. J Am Vet Med Assoc, 234: 1130-1139.
doi: 10.2460/javma.234.9.1130
-
Warfield K L, Swenson D L, Negley D L, Schmaljohn A L, Aman M J, and Bavari S. 2004. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine, 22: 3495-3502.
doi: 10.1016/j.vaccine.2004.01.063
-
Warfield K L, Swenson D L, Olinger G G, Kalina W V, Aman M J, and Bavari S. 2007. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis, 196 Suppl 2: S430-437.
-
Warfield K L, Bosio C M, Welcher B C, Deal E M, Mohamadzadeh M, Schmaljohn A, Aman M J, and Bavari S. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A, 100: 15889-15894.
doi: 10.1073/pnas.2237038100
-
Warfield K L, Olinger G, Deal E M, Swenson D L, Bailey M, Negley D L, Hart M K, and Bavari S. 2005. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol, 175: 1184-1191.
doi: 10.4049/jimmunol.175.2.1184
-
Warfield K L, Perkins J G, Swenson D L, Deal E M, Bosio C M, Aman M J, Yokoyama W M, Young H A, and Bavari S. 2004. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med, 200: 169-179.
doi: 10.1084/jem.20032141
-
Warfield K L, Posten N A, Swenson D L, Olinger G G, Esposito D, Gillette W K, Hopkins R F, Costantino J, Panchal R G, Hartley J L, Aman M J, and Bavari S. 2007. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis, 196 Suppl 2: S421-429.
-
Yasuda J, Nakao M, Kawaoka Y, and Shida H. 2003. Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol, 77: 9987-9992.
doi: 10.1128/JVI.77.18.9987-9992.2003